标题
Managing The Skin Toxicities From New Melanoma Drugs
作者
关键词
Ipilimumab, Vemurafenib, Dabrafenib, Trametinib, Skin toxicities, Melanoma
出版物
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 15, Issue 2, Pages 281-301
出版商
Springer Nature
发表日期
2014-05-27
DOI
10.1007/s11864-014-0284-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
- (2013) L. Boussemart et al. ANNALS OF ONCOLOGY
- Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors
- (2013) R. Anforth et al. BRITISH JOURNAL OF DERMATOLOGY
- Immune toxicities and long remission duration following ipilimumab therapy for metastatic melanoma: two illustrative cases
- (2013) H. Assi et al. Current Oncology
- Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4
- (2013) Alyssa Fischer et al. Dermatologic Therapy
- Vemurafenib: an unusual UVA-induced photosensitivity
- (2013) Pauline Gelot et al. EXPERIMENTAL DERMATOLOGY
- Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy
- (2013) Imke Satzger et al. JOURNAL OF CLINICAL ONCOLOGY
- Erythema Nodosum–Like Panniculitis in Patients With Melanoma Treated With Vemurafenib
- (2013) Rishika Sinha et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Sweet syndrome: Clinical presentation, associations, and response to treatment in 77 patients
- (2013) Nicole M. Rochet et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Eruptive milia secondary to vemurafenib
- (2013) Brittany L. Sambrano et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
- (2013) Courtney J. Ensslin et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy
- (2013) Sofya Pintova et al. MELANOMA RESEARCH
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
- (2013) M. E. Lacouture et al. ONCOLOGIST
- Vemurafenib-Induced DRESS
- (2013) Kurt S. Wenk et al. JAMA Dermatology
- Tracking of Second Primary Melanomas in Vemurafenib-Treated Patients
- (2013) Stephane Dalle et al. JAMA Dermatology
- Cutaneous effects of BRAF inhibitor therapy: a case series
- (2012) P. L. Mattei et al. ANNALS OF ONCOLOGY
- Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management
- (2012) Lisa Zimmer ARCHIVES OF DERMATOLOGY
- Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
- (2012) R.M. Anforth et al. BRITISH JOURNAL OF DERMATOLOGY
- Systemic Retinoid Therapy for Chemoprevention of Nonmelanoma Skin Cancer in a Patient Treated With Vemurafenib
- (2012) Rachael Anforth et al. JOURNAL OF CLINICAL ONCOLOGY
- Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
- (2012) Grégoire Berthod et al. JOURNAL OF CLINICAL ONCOLOGY
- Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition
- (2012) Lisa Zimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Oncogenic Drivers and the Immune System in Melanoma
- (2012) Grant A. McArthur et al. JOURNAL OF CLINICAL ONCOLOGY
- Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma
- (2012) Kevin P. Boyd et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Eccrine squamous syringometaplasia associated with vemurafenib therapy
- (2012) Scott G. Story et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Vasculitis and panniculitis associated with vemurafenib
- (2012) Roberto A. Novoa et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
- (2012) Emily Y. Chu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Cutaneous toxicities of RAF inhibitors
- (2012) Rachael Anforth et al. LANCET ONCOLOGY
- Vemurafenib Sensitivity Skin Reaction after Ipilimumab
- (2012) James J. Harding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ultraviolet A and Photosensitivity during Vemurafenib Therapy
- (2012) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
- (2011) Wouter V. Vogel et al. JOURNAL OF CLINICAL ONCOLOGY
- Antagonistic T-Cell Subsets in Skin Diseases
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Staging and Prognosis of Cutaneous Melanoma
- (2010) Paxton V. Dickson et al. Surgical Oncology Clinics of North America
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
- (2008) A. Eckert et al. DERMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started